Electron microscopy evidence that cytoplasmic localization of the p16^INK4A “nuclear” cyclin-dependent kinase inhibitor (CKI) in tumor cells is specific and not an artifact. A study in non-small cell lung carcinomas

References

• Adams PD (2001) Regulation of the retinoblastoma tumor suppressor protein by cyclin/cdks. Biochim. Bio- phys. Acta 1471: 123 - 133.
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C (1995) Mutations of cell cycle regula- tors. Am. J. Pathol. 147: 545–560.
   PubMed Web of Science ®Google Scholar
• Emig R, Magener A, Ehemann V, Meyer A, Stilgen- bauer F, Volkmann M, Wallwiener D, Sinn HP (1998) Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumor pro- liferation. Br. J. Cancer 78: 1661- 1668.
   PubMed Web of Science ®Google Scholar
• Evangelou K, Balaskas C, Marinos E, Dosios T, Kittas C, Gorgoulis VG (2002) Immunohistochemical localiza- tion of c-mos at the light and electron microscope level in non-small cell lung carcinomas. Biotech. Histochem. 77: 85–91.
   PubMed Web of Science ®Google Scholar
• Fabbro M, Henderson BR (2003) Regulation of tumor suppressors by nuclear-cytoplasmic shuttling. Exp. Cell Res. 282: 59–69.
   PubMed Web of Science ®Google Scholar
• Galea MA, Eleftheriou A, Henderson BR (2001) ARMdomain-dependent nuclear import of adenomatous poly- posis coli protein is stimulated by the B56a subunit of protein phosphatase 2A. J. Biol. Chem. 276: 45833–45839. Geradts J, Kratzke RA, Niehans GA, Lincoln CE (1995) Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res. 55: 6006–6011.
   Google Scholar
• Gorgoulis VG, Zacharatos P, Kotsinas A, Liloglou T, Kyroudi A, Veslemes M, Rassidakis A, Halazonetis T,
   Google Scholar
• Field J, Kittas C (1998a) Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non- small cell lung carcinomas. Relationship with p53 and MDM2 protein expression. Am. J. Pathol. 153: 1749–1765. Gorgoulis VG, Koutroumbi EN, Kotsinas A, Zacharatos P, Markopoulos C, Giannikos L, Kyriakou V, Voulgaris Z, Gogas I, Kittas C (1998b) Alterations of p16-pRb pathway and chromosome locus 9p21-22 in sporadic invasive breast carcinomas. Mol. Med. 4: 807–822.
   Google Scholar
• Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G, Bartek J (1995) Retinoblastoma- protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 375: 503 - 510.
   PubMed Web of Science ®Google Scholar
• Mariatos G, Gorgoulis VG, Zacharatos P, Kotsinas A, Vogiatzi T, Rassidakis G, Foukas P, Liloglou T, Tiniakos D, Angelou N, Manolis EN, Veslemes M, Field JK, Kittas C (2000) Expression of p16(INK4A) and alterations of the 9p21-23 chromosome region in non-small-cell lung carcinomas: relationship with tumor growth parameters and ploidy status. Int. J. Cancer 89 20: 133–141.
   Google Scholar
• Milde-Langosch K, Bamberger AM, Rieck G, Kelp B, Loning T (2001) Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype. Breast Cancer Res. Treat. 67: 61–70. Moll UM, Riou G, Levine AJ (1992) Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc. Natl. Acad. Sci. 89: 7262–7266.
   Google Scholar
• Moll UM, LaQuaglia M, Benard J, Riou G (1995) Wild- type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc. Natl. Acad. Sci. 92: 4407–4411.
   Google Scholar
• Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753–756.
   Google Scholar
• Park M, Chae HD, Yun J, Jung M, Kim YS, Kim SH, Han MH, Shin DY (2000) Constitutive activation of cyclin B1-associated cdc2 kinase overrides p53-mediated G2-M arrest. Cancer Res. 60: 542 - 545.
   PubMed Web of Science ®Google Scholar
• Ruas M, Peters G (1998) The p16^INK4A/CDKN2A tumor suppressor and its relatives. Biochem. Biophys. Acta 1378: 115–177.
   Google Scholar
• Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13: 1501- 1512.
   Google Scholar
• Shim YH, Kang GH, Ro JY (2000) Correlation of p16hypermethylation with p16 protein loss in sporadic gastric carcinomas. Lab. Invest. 80: 689–695.
   PubMed Web of Science ®Google Scholar
• Taylor WR, Stark GR (2001) Regulation of the G2/M transition by p53. Oncogene 20: 1803–1815.
   PubMed Web of Science ®Google Scholar
• Zhao Po, Ying-Chuan Hu, Talbot IC (2003) Expressingpatterns of p16 and CDk4 correlated to prognosis in colorectal carcinoma. World J. Gastroenterol. 9: 2202- 2206.
   PubMed Web of Science ®Google Scholar